Chiron’s Fluvirin Distribution Contracts Under Discussion
This article was originally published in The Pink Sheet Daily
Executive Summary
The company and its vaccine distributors will determine whether contracts for 2004 will be extended for the next flu season given uncertainty over whether Fluvirin will be available. Additional clarity on Fluvirin supply is expected in “early spring.”
You may also be interested in...
Fluvirin FDA Manufacturing Inspections Expected By July
Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.
Fluvirin FDA Manufacturing Inspections Expected By July
Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.
GMP Warning Letters With Unusual Language Are Red Flags, Attorney Says
Companies should pay attention to non-boilerplate language inserted at the end of a warning letter, which could signal FDA's intent to pursue more serious enforcement action, Sidley Austin's Bonner says during Drug & Device Dialogue audio conference. A "quiet period" in communications with FDA can precede a seizure, he warns.